![]() |
|
|
Vol. 289, Issue 1, 417-426, April 1999
Department of Pharmacology,
| |
Abstract |
|---|
|
|
|---|
The antinociceptive action of the alkaloid
cis-8,10-di-n-propyllobelidiol
hydrochloride dehydrate (DPHD), isolated from Siphocampylus verticillatus, given i.p., p.o., i.t., or i.c.v., was assessed in chemical and thermal models of nociception in mice, such as acetic
acid-induced abdominal constriction, formalin- and capsaicin-induced licking, and hot-plate and tail-flick tests. DPHD given by i.p., p.o.,
i.t., or i.c.v. elicited significant and dose-related antinociception. At the ID50 level, DPHD was about 2- to 39-fold more potent
than aspirin and dipyrone, but it was about 14- to 119-fold less potent than morphine. Its analgesic action was reversed by treatment of
animals with p-chlorophenylalanine, naloxone, cyprodime,
naltrindole, nor-binaltrorphimine, L-arginine, or pertussis
toxin. Its action was also modulated by adrenal-gland hormones but was
not affected by
-aminobutyric acid type A or type B antagonist,
bicuculine, or phaclofen, nor was it affected by glibenclamide. DPHD,
given daily for up to 7 days, did not develop tolerance to itself nor did it induce cross-tolerance to morphine. However, animals rendered tolerant to morphine presented cross-tolerance to DPHD. The
antinociception of DPHD was not secondary to its anti-inflammatory
effect, nor was it associated with nonspecific effects such as muscle
relaxation or sedation. DPHD, in contrast to morphine, did not decrease
charcoal meal transit in mice, nor did it inhibit electrical field
stimulation of the guinea pig ileum or mouse vas deferens in vitro.
Thus, DPHD produces dose-dependent and pronounced systemic, spinal, and
supraspinal antinociception in mice, including against the neurogenic
nociception induced by formalin and capsaicin. Its antinociceptive
effect involves multiple mechanisms of action, namely interaction with
µ,
, or
opioid systems, L-arginine-nitric oxide
and serotonin pathways, activation of Gi protein sensitive to pertussis toxin, and modulation by endogenous glucocorticoids.
| |
Introduction |
|---|
|
|
|---|
The
plants of the family Campanulaceae consist of approximately 29 genera
and more than 1200 species that are distributed in tropical and
subtropical countries (Wimmer, 1956
). Siphocampylus verticillatus, a member of this family, is a native plant which grows abundantly in the South of Brazil. Among the main traditional medicinal uses of this plant, its beneficial use in the management of
asthma is reported (Garello, 1950
).
We have reported previously that the extract obtained from the aerial
parts of S. verticillatus causes significant dose-related and long-lasting oral antinociception when assessed against both neurogenic and inflammatory models of nociception in mice (Trentin et
al., 1997
). The precise mechanism underlying the analgesic action of
the extract of S. verticillatus still remains unclear, but a
great part of this effect seems to be related to an opioid-like action,
in addition to an involvement of the nitric oxide pathway (Trentin et
al., 1997
). In a subsequent study, we have isolated and identified by
X-ray crystallography the major naturally occurring substance from this
plant, identified as being a new alkaloid and denoted as
cis-8,10-di-N-propyllobelidiol hydrochloride
dehydrate (DPHD; Miguel et al., 1996
).
In this study, we have evaluated the antinociceptive properties and
also some of the mechanisms that underlie the antinociceptive action of
a novel alkaloid, DPHD, isolated from S. verticillatus (Fig.
1) by comparing its antinociceptive
action with some well known standard analgesic drugs in thermal and
chemical models of nociception in mice. Attempts have also been made to
assess to what extent the antinociception caused by DPHD, like that
caused by morphine, is associated with inhibition of nerve-mediated
contractions in the guinea pig ileum and mice vas deferens in vitro, as
well against the intestinal transit in mice in vivo.
|
| |
Materials and Methods |
|---|
|
|
|---|
Animals
Male Swiss mice (25-35 g) and albino guinea pigs of either sex
(350-550 g), housed at 22 ± 2°C under a 12 h light/12
dark cycle and with access to food and water ad libitum, were used throughout the experiments. Mice were acclimated to the laboratory for
at least 1 h before testing and were used once throughout the
experiments. The experiments reported were carried out in accordance
with the current guidelines for the care of laboratory animals and the
ethical guidelines for investigations of experimental pain in conscious
animals (Zimmermann, 1983
).
Pharmacological Analysis
In Vivo Experiments.
Acetic acid-induced abdominal
constriction. The abdominal constrictions resulting from i.p.
injection of acetic acid (0.6%) were similar to that described
previously (Corrêa et al., 1996
; Vaz et al., 1996
). Animals were
pretreated with DPHD (29.1-582.2 µmol/kg) or with vehicle (10 ml/kg)
0.5 (i.p.) and 1 (p.o.) h before injection of acetic acid. After the
challenge, pairs of mice were placed in separate boxes and the number
of abdominal constrictions was cumulatively counted over a period of 20 min after acetic acid injection.
Formalin test.
The procedure used was essentially similar to
that described previously (Corrêa and Calixto, 1993
; Vaz et al.,
1996
; Santos and Calixto, 1997
). Twenty microliters of 2.5% formalin
solution (0.92% of formaldehyde), made up in PBS (NaCl 137 mM, KCL 2.7 mM, and phosphate buffer, 10 mM), was injected intraplantarly under the
surface of the right hindpaw. Animals were treated with DPHD
(8.7-582.2 µmol/kg) or with vehicle (10 ml/kg) by i.p. or p.o.
routes, 0.5 and 1 h before formalin injection, respectively. Other
groups of animals were treated with DPHD (29.1-291.1 nmol/site) or
with vehicle (5 µl/site) by i.c.v. or i.t. routes, as described previously (Hylden and Wilcox, 1980
; Vaz et al., 1996
, Santos and
Calixto, 1997
), 10 min before formalin injection. After intraplantar injection of formalin, the animals were immediately placed in a glass
cylinder 20 cm in diameter and the time spent licking the injected paw
was timed with a chronometer and considered indicative of pain. To
investigate whether the antinociceptive activity of DPHD in
formalin-induced pain was associated with antiedematogenic activity, at
the end of all experiments the animals were sacrificed by cervical
dislocation 30 min after formalin injection, and the paw was cut at the
knee joint and weighed on an analytical balance (Santos and Calixto,
1997
).
Capsaicin-induced pain.
In an attempt to provide more direct
evidence concerning the possible antinociceptive effect of DPHD on
neurogenic pain, we also investigated whether DPHD antagonized
capsaicin-induced pain in the mouse paw. The procedure used was similar
to that described previously (Corrêa et al., 1996
, Santos and
Calixto, 1997
). Twenty microliters of capsaicin (1.6 µg/paw made in
PBS) was injected intraplantarly under the surface of the right
hindpaw. Animals were observed individually for 5 min after capsaicin
injection. The amount of time spent licking the injected paw was timed
with a chronometer and was considered indicative of pain. Animals were treated either with i.p. or p.o. injection of vehicle (10 ml/kg) or
DPHD (29.1-582.2 µmol/kg), or with indomethacin (2.8-27.9 µmol/kg i.p.) or morphine (1.5-15.5 µmol/kg s.c.), 0.5 and 1 h before capsaicin injection. Other groups of animals were treated with DPHD
(29.1-291.1 nmol/site) or with vehicle (5 µl/site) by i.c.v. or i.t.
routes 10 min before capsaicin injection.
Hot-plate test.
The hot-plate test was used to measure the
response latencies according to the method described previously (Vaz et
al., 1996
; Beirith et al., 1998
). The reaction time was recorded for
mice pretreated with vehicle (10 ml/kg i.p., 5 µl/site i.t. or
i.c.v.), DPHD (291.1 µmol/kg i.p., 291.1 nmol/site i.t. or i.c.v.),
or morphine (31.0 µmol/kg s.c. 15.5 nmol/site i.t. or i.c.v.)
0.5 h and 10 min before the tests. All animals were selected
1 h before the test on the basis of their reactivity in the model
by eliminating those mice that remained on the apparatus (maintained at
50°C) for up to 15 s. Each animal was used as its own control. A
latency period (cut-off) of 30 s was defined as complete analgesia.
Tail-flick test.
A radiant heat tail-flick analgesiometer
was used to measure response latencies according to the method
described previously (Vaz et al., 1996
; Beirith et al., 1998
). The
reaction time was recorded for control (saline injection) mice or in
animals pretreated with DPHD (291.1 µmol/kg i.p.) or with morphine
(31.0 µmol/kg s.c.) 0.5 h before the tests. All animals were
selected 24 h before the test on the basis of their reactivity in
the model by eliminating those mice that remained on the apparatus for
up to 8 s. A latency period (cut-off) of 20 s was defined as
complete analgesia.
Rota-rod test.
To evaluate the possible nonspecific
muscle-relaxant or sedative effects of DPHD, the mice were tested on
the rota-rod, as described previously (Vaz et al., 1996
; Beirith et
al., 1998
). The animals were selected 24 h before to the test by
eliminating those mice that did not remain on the bar for two
consecutive periods of 60 s. Animals were treated with DPHD (291 µmol/kg i.p.) or with saline injection (10 ml/kg i.p.) 30 min before
being tested. Results are expressed as the times for which animals
remained on the rota-rod. The cut-off time used was 60 s.
Gastrointestinal transit.
To test the possible effects of
DPHD, in the gastrointestinal motility, the mice were fasted for
24 h after the gastrointestinal transit was analyzed, as described
previously (Shannon et al., 1997
). The animals were treated with
DPHD (87.3 µmol/kg i.p.) or with morphine (15.5 µmol/kg s.c.)
0.5 h after being given a standard charcoal meal (0.3 ml) by
gavage. The mice were sacrificed 20 min after administration of the
charcoal meal and the distance the charcoal meal had traveled was
measured. Data were expressed as the percentage of the gut the charcoal
meal traveled. Control animals received the same volume of saline
injection (10 ml/kg i.p.) 30 min before being tested.
Analysis of the possible mechanism of action of DPHD.
To
investigate the participation of the opioid system in the
antinociceptive effect of DPHD, animals were pretreated with naloxone,
a nonselective opioid receptor antagonist (3.0 µmol/kg i.p.);
cyprodime, a selective µ opioid receptor antagonist (2.3 µmol/kg
i.p.); naltrindole, a selective
opioid receptor antagonist (2.2 µmol/kg i.p.); or nor-binaltrorphimine, a selective
opioid receptor antagonist (1.4 µmol/kg i.p.) 15 min before administration of DPHD (87.3 µmol/kg i.p.), morphine (15.5 µmol/kg s.c.), or saline (10 ml/kg i.p.) injection, as reported previously (Craft et al.,
1995
; Frey and Schicht, 1996
; Ossipov et al., 1996
). The other groups
of animals received DPHD, morphine, naloxone, naltrindole, nor-binaltrorphimine, or saline 0.5 h before the formalin injection.
-aminobutyric acid
(GABA) system, animals were treated with DPHD (87.3 µmol/kg i.p.), muscimol, a selective GABAA receptor
agonist (8.7 µmol/kg i.p.), or with bachofen, a selective
GABAB receptor agonist (4.6 µmol/kg i.p.)
0.5 h before injection of formalin. The animals received
bicuculine, a GABAA receptor antagonist (1.9 µmol/kg i.p.), or phaclofen, a GABAB receptor
antagonist (40.0 µmol/kg i.p.), 15 min before administration of DPHD,
baclofen, muscimol, or saline injection, as reported previously
(Shafizadeh et al. 1997In Vitro Experiments. Guinea pig ileum field stimulation. Albino guinea pigs were stunned by a blow on the head and were bled. A portion of ileum 10 to 30 cm from the ileo-cecal junction was excised rapidly and was flushed gently with warm Krebs' solution (composition: NaCl, 118 mM; KCl, 4.8 mM; CaCl2, 2.5 mM; MgSO4, 1.2 mM; KH2PO4, 0.9 mM; NaHCO3, 25 mM, and glucose, 11 mM; pH 7.4) to remove contents and adhering adipose tissue. Whole segments (1-3 cm long, 6-8 segments per animal) were set up for recording of isometric contractions along their longitudinal axis in a jacketed organ bath containing 5 ml of gassed (5% CO2 in O2) Krebs' solution maintained at 37°C, under a basal tension of 1 g. Isometric responses were measured by means of TRI-201 force displacement transducers and were recorded on a polygraph (Letica Scientific Instruments, Barcelona, Spain).
After at least 30 min of equilibration, with renewals of the solution every 10 min, preparations were submitted to field stimulation with rectangular 1-ms pulses of supramaximal voltage (ca. 50-70 V), delivered at 0.1 Hz via platinum electrodes (Guimarães and Rae, 1992Mouse vas deferens field stimulation. Male Swiss mice were lightly anesthetized with ether and sacrificed by a blow on the head and cervical dislocation. Both vasa deferentia were removed and freed of adhering connective and adipose tissue, and were then placed in a Petri dish containing warm physiological salt solution (composition: NaCl, 118 mM; KCl, 4.8 mM; CaCl2, 2.5 mM; KH2PO4, 0.9 mM; NaHCO3, 25 mM; and glucose, 11 mM; pH 7.2-7.4). Each vas deferens was then transferred to an organ bath containing 5 ml of gassed (5% CO2 in O2) Krebs' solution (see concentration above) at 37°C, under a basal tension of 0.5 g. Isometric responses were measured by means of TRI-201 force displacement transducers and were recorded on a polygraph (Letica Scientific Instruments).
At least 45 min of equilibration was allowed before any drug additions, during which the bath solution was renewed every 15 min. Field stimulation was induced with trains of four rectangular 0.5-ms pulses of supramaximal voltage (ca. 20-40 V), delivered at 10 Hz every 20 s via platinum electrodes, as described before (Rae and Calixto, 1990Drugs
The following drugs were used: formalin and morphine
hydrochloride (Merck, AG, Darmstadt, Germany);
DL-p-chlorophenylalanine methyl ester
hydrochloride, pertussis toxin, 2,2,2-tribromoethanol, L-ARG,
NG-nitro-L-arginine, and
capsaicin (Sigma Chemical Co., St. Louis, MO); glibenclamide, naloxone
hydrochloride, cyprodime hydrobromide, naltrindole hydrochloride,
nor-binaltrorphimine dihydrochloride, baclofen, and phaclofen (Research
Biochemicals International, Natick, MA); and muscimol and bicuculine
(Tocris, Balwin, MO). DPHD was isolated from stems and leaves of
S. verticillatus in the Chemistry Department of the Federal
University of Santa Catarina, Brazil, as described previously (Miguel
et al., 1996
). Its degree of purity was higher than 98%. Drugs were
dissolved in 0.9% NaCl solution, with the exception of indomethacin
and capsaicin, which were dissolved in Tween 80 and absolute ethanol,
respectively. All drugs were prepared just before use in 0.9% (w/v)
NaCl solution. The final concentration of Tween and ethanol did not
exceed 5% and did not cause any effect per se.
Statistical Analysis
Results are presented as mean ± S.E.M. except the
ID50 or the IC50 values
(i.e., the dose or the concentration of drugs reducing the pain or
twitch responses by 50% in relation to the control value), which are
reported as geometric means accompanied by their respective 95%
confidence limits. The statistical significance between groups was
calculated by means of analysis of variance followed by Dunnett's
multiple comparison test or by Newman-Keuls' test when appropriate.
P values less than 0.05 (P < .05) were considered as indicative of significance. The
ID50 or the IC50 values
were determined by linear regression from individual experiments with
linear regression GraphPad software (1994; San Diego, CA). Hot-plate and tail-flick latencies were converted to percentage of
maximum possible effect with the following equation: MPE% = 100 × (postdrug latency
predrug latency)/(cut-off time
predrug latency) (Vaz et al., 1996
).
| |
Results |
|---|
|
|
|---|
Acetic Acid-Induced Abdominal Constriction
The results of Fig. 2 and the data
summarized in Table 1 show that DPHD
given by i.p. or by p.o. routes produced significant inhibition of
acetic acid-induced abdominal constrictions. Given orally, DPHD was
2.6-fold less potent than when it was given by i.p. route.
|
|
Formalin-Induced Pain
The results shown in Fig. 3 and data
summarized in Table 1 show that DPHD given by i.p. or p.o. routes
caused significant inhibition of the early (0 to 5 min) and the late
phase (15 to 30 min) of the formalin-induced licking. DPHD was more
potent and efficacious in inhibiting the inflammatory than the
neurogenic component of the formalin pain response. Given orally, DPHD
was 5-fold less potent than when it was given i.p. in relation to the
late phase of the formalin test (Table 1). Independent of the route of
administration used, DPHD failed to affect the edematogenic response
associated with the second phase of the formalin test (results not
shown). The antinociceptive effect of DPHD was long-lasting and
significant when given by i.p. (6 h) or p.o. (8 h) routes (results not
shown).
|
The i.c.v. or i.t. injection of DPHD inhibited both phases of
formalin-induced licking (Fig. 4).
However, at the ID50 level, DPHD was about 14- to
112-fold less potent than morphine when assessed against the first and
the second phase of the formalin test, respectively (Table 1).
|
Capsaicin-Induced Pain
The results shown in Fig. 5 and data
summarized in Table 1 show that DPHD (given by i.p., p.o., i.c.v., or
i.t. routes) or morphine (given by s.c. route) caused significant
inhibition of capsaicin-induced licking. However, at the
ID50 level, DPHD was about 31- to 119-fold less
potent than morphine, but it was 2- to 3.5-fold more potent than
dipyrone depending on the route of administration used when assessed
against capsaicin-induced licking. Interestingly, indomethacin given
i.p. had no significant analgesic effect in this model (Fig. 5A).
|
Hot-Plate and Tail-Flick Tests
The results summarized in Table 2 show that DPHD (given by i.p., i.c.v., or i.t. routes) did not cause any significant change in the latency response in either hot-plate test or tail-flick assays. In contrast, morphine (given s.c., i.c.v., or i.t.) caused a significant and marked increase in the pain latency in both algesiometer assays (Table 2).
|
Rota-Rod Test
DPHD given by i.p. route did not significantly affect the motor response of animals. Control response in the rota-rod test was 59.1 ± 0.7 s versus 58.5 ± 1.0 s in the presence of tested compound (n = 7 in each group).
Effect of Several Classes of Drugs
Formalin-Induced Pain.
The results in Fig.
6 show that the pretreatment of animals
with naloxone before injection of morphine or DPHD largely reverted the
antinociception caused by either morphine or DPHD against both phases
of the formalin test. However, the pretreatment of animals with
cyprodime significantly reverted the antinociceptive effect caused by
either morphine or DPHD when assessed against the late (but not the
first) phase of the formalin test. In addition, pretreatment of animals
with naltrindole or with nor-binaltrorphimine before injection of
morphine or DPHD significantly reversed the antinociception caused by
DPHD, but did not significantly change the antinociceptive action
caused by morphine when assessed against both phases of the formalin
test (Fig. 6). The pretreatment of animals with L-ARG also
significantly reversed the antinociception caused by either
L-NOARG or DPHD assessed against both phases of the
formalin test. The same treatment with L-ARG also
significantly reversed the antinociceptive action of the morphine when
assessed against the second (but not the first) phase of the formalin
test (Fig. 7).
|
|
|
|
|
Responses to Field Stimulation. Electrical field stimulation of the guinea pig ileal segments or mouse vas deferens induced twitch contractions, which were abolished by tetrodotoxin (1 µM; n = 4 for each group, results not shown). Cumulative additions of morphine (1 nM-10 µM) induced concentration-dependent depression of contraction evoked by field stimulation in ilea segments (n = 9 per group), with a mean IC50 value of 25.6 (4.8-137.4) nM and maximal inhibition of 87.5 ± 2.9%. Single additions of morphine (1 nM-10 µM) also caused a concentration-dependent depression of contractions evoked by field stimulation in mouse vas deferens (n = 8 per group), with a mean IC50 value of 2.5 (0.8-8.4) µM and maximal inhibition of 65.0 ± 4.5% (results not shown). In contrast, cumulative or single additions of DPHD (1 nM-10 µM; n = 5-8 per group) caused a discrete (10 to 20%) inhibition of the contractions evoked by field stimulation in either guinea pig ilea segments or in mouse vas deferens (results not shown).
| |
Discussion |
|---|
|
|
|---|
We have recently isolated and characterized, by means of X-rays
and also by use of several chemical procedures, a novel alkaloid from
the aerial parts of S. verticullatus (Campanulaceae),
denoted as being the
cis-8,10-di-N-propyllobelidiol hydrochloride
dehydrate (C16H34NO2+·Cl
·2H2O)
(Miguel et al., 1996
). In an earlier study (Trentin et al., 1997
), we
reported that the extract of S. verticillatus given either
orally or i.p. produced long-lasting antinociception when assessed in
chemical (but not in thermal) models of nociception in mice such as
acetic acid-induced abdominal constriction or formalin- and
capsaicin-induced nociception. The antinociception caused by the
extract of S. verticillatus in the formalin test was found,
at least partly, to be related to an opioid-like action. An involvement
of the L-arginine-nitric oxide pathway was also suggested. These observations were substantiated by the demonstration that the extract analgesic action was largely reversed by
naloxone and by a nitric oxide precursor, L-ARG.
In addition, it was also demonstrated that the endogenous
glucocorticoids probably account for the antinociception caused by the
extract of S. verticillatus, as revealed by the significant
attenuation of its antinociceptive action after bilateral adrenalectomy
of animals (Trentin et al., 1997
).
Here we report for the first time the antinociception caused by the
major constituent isolated from this plant, the new alkaloid denoted as
cis-8,10-di-N-propyllobelidiol hydrochloride
dehydrate (Miguel et al., 1996
). As shown for the extract of S. verticillatus (Trentin et al., 1997
), this alkaloid, given by
p.o., i.p., i.t., or i.c.v. routes produces dose-related and
significant antinociception when assessed in chemical assays of
nociception, including the neurogenic pain caused by formalin (first
phase) and capsaicin in mice. However, given in similar doses, this
alkaloid is largely ineffective in producing antinociception when
assessed systemically, spinally, and supraspinally in the thermal
models of pain, namely, the tail-flick and hot-plate tests.
The fact that this new alkaloid, given by different routes, exhibits
significant antinociception when assessed against the neurogenic (first
phase of formalin test) and capsaicin-induced algesic response seems to
be relevant. It has been well documented that the majority of the
nonsteroidal anti-inflammatory drugs so far analyzed are usually
ineffective in preventing the neurogenic pain caused by either formalin
or capsaicin (Hunskaar and Hole, 1987
; Shibata et al., 1989
; Malmberg
and Yaksh, 1992
; Corrêa and Calixto, 1993
; Corrêa et al.,
1996
; Vaz et al., 1996
). However, at the ID50
level, DPHD was about 14- to 119-fold less potent than morphine, but it
was about 2- to 39-fold more potent than aspirin, acetaminophen, or
dipyrone, depending on the route of administration used (Vaz et al.,
1996
, Beirith et al., 1998
).
Attempts have also been made in the present study to investigate by use
of several in vivo and in vitro pharmacological procedures some of the
mechanisms underlying the antinociception caused by this alkaloid.
Results of the current study confirm and extend our previous evidence
(Trentin et al., 1997
) by demonstrating that the activation of the
opioid naloxone-sensitive pathway is most likely involved in the
antinociception caused by this alkaloid, indicated by the finding that
naloxone almost fully reversed the antinociception action of DPHD. By
using a more selective opioid antagonist, it was possible to
demonstrate that DPHD antinociceptive action involves the µ,
, and
opioid receptors. This evidence derives from the fact that
cyprodime, naltrindole, or nor-binaltrorphimine significantly inhibited
DPHD antinociception according to the formalin test (Craft et al.,
1995
; Frey and Schicht, 1996
; Ossipov et al., 1996
). Another piece of
evidence suggesting the involvement of opioid-like substances in the
antinociception caused by DPHD was its marked cross-tolerance with
morphine in animals that had received an s.c. injection of this opioid
once a day for 7 consecutive days (Ménard et al., 1995
).
Interestingly, treatment of animals with DPHD once a day for 7 days did
not cause any tolerance to the alkaloid itself, or even cross tolerance
with morphine. However, despite similarities with the action of
opioid-like drugs, DPHD, surprisingly, was completely devoid of
analgesic action when it was assessed in two thermal models of
nociception and also in intestinal transit, as well as inhibiting the
field-stimulated neurogenic contractions in the isolated guinea pig
ileum and mouse vas deferens. Under very similar conditions, morphine
caused marked antinociception and reduced intestinal transit, producing
concentration-dependent inhibition of the twitch contractions in both
guinea pig ileum and mouse vas deferens. The reason for such discrepant
findings still remains unclear and was not further investigated in the present study.
In addition, results of the present study provide evidence supporting
the involvement of the serotoninergic system in the antinociceptive
effect of DPHD, as revealed by the finding that pretreatment of animals
with PCPA at a dose known to inhibit the cortical content of serotonin
and to significantly reverse the morphine antinociception largely
antagonized this alkaloid antinociception (Taber and Latranyi, 1981
;
Vonvoigtlander et al., 1984
; Pini et al., 1996
; Rattray et al., 1996
;
Trentin et al., 1997
; present study). In addition, our results also
support the notion that the L-ARG-nitric oxide pathways
might account for the antinociceptive effect of DPHD. This view derives
from the fact that treatment of animals with the nitric oxide precursor
L-ARG largely reversed the antinociception caused by DPHD
(both phases) and by morphine (second phase) as well the
antinociceptive effect caused by L-NOARG, a known nitric
oxide inhibitor, when assessed in the formalin test. Very similar
findings have been reported for morphine- and L-NOARG-induced antinociception (Kawabata et al., 1993
;
Moore et al., 1993
; Vaz et al., 1996
; Trentin et al., 1997
; present study). However, the antinociception elicited by DPHD seems to be
independent of interaction with GABAA or
GABAB receptors. These notions are because
bicuculine and phaclofen, a selective GABAA and
GABAB receptor antagonist under conditions
in which it antagonized muscimol- and baclofen-induced antinociception,
respectively, did not affect DPHD antinociception (Sawynok, 1984
;
Malcangio et al., 1991
; Vaz et al., 1996
; Shafizadeh et al., 1997
;
present study). The opening of ATP-sensitive potassium channels also
does not appear to play a major role in DPHD-induced antinociception because the treatment of animals with glibenclamide, under conditions in which the antinociception caused by morphine was markedly reversed, had no effect on DPHD antinociceptive action when assessed against either phase of the formalin test (Ocanã and Baeyens, 1993
; Raffa and Martinez, 1995
; Shewade and Ramaswamy, 1995
; present study). Also,
the antinociception caused by DPHD is not the consequence of possible
nonspecific central or peripheral depressant effects, as revealed by
the lack of any detectable nonspecific effect in the rota-rod test.
The mechanism by which DPHD produces systemic, spinal, or supraspinal
antinociception in mice is still not completely understood at this
stage of our study. However, the current results show that a large part
of its antinociceptive effect was significantly antagonized by i.c.v.
treatment of animals with pertussis toxin (1 µg/site, 7 days before
the experiments) at a dose which has been demonstrated previously to
suppress the antinociceptive effect caused by morphine through ADP
ribosylation (Przewlocki et al., 1987
; Parolaro et al., 1990
;
Sánchez-Blázquez and Garzón, 1991
; Shah et al., 1994
,
1997
; Hernandez et al., 1995
; Tseng and Collins, 1996
; present study).
Therefore, such results indicate that DPHD antinociception, similar to
that of morphine, is coupled to the same signal transduction system,
namely Go/Gi-pertussis
toxin-sensitive mechanisms. Also relevant are the findings showing that
DPHD, like the antinociceptive effect caused by the extract of S. verticillatus, is modulated by endogenous glucorticoids from gland
hormones because previous bilateral adrenalectomy of animals carried
out 1 week before testing significantly prevented its analgesic action
in comparison with sham-operated animals.
In summary, data from the current study extend our previous findings
(Trentin et al., 1997
) and show that the major naturally occurring
constituent isolated from the aerial parts of the Brazilian medicinal
plant S. verticillantus, the new alkaloid denoted DPHD, produces systemic, spinal, and supraspinal antinociception when assessed in chemical (acetic acid-, formalin-, and capsaicin-induced pain), but not in thermal, models of nociception in the mouse. Several
mechanisms account for its antinociceptive action, such as an
interaction with opioid-like substances, i.e., through µ,
, and
receptors, involvement of serotoninergic and nitrergic systems, and
also a modulatory action exerted by endogenous glucocorticoids. However, an interaction with GABAA or
GABAB receptors, or with ATP-sensitive potassium
channels, is unlikely to be involved with the antinociception caused by
DPHD. Finally, the biochemical mechanism involved in the
antinociception produced by DPHD, like that of morphine, seems to
involve an interaction with
Gi/Go-dependent mechanisms
sensitive to treatment with pertussis toxin.
| |
Acknowledgments |
|---|
We are grateful to Rosana Maria Ostroski for in vitro technical assistance. A.R.S. Santos is a Ph.D. student in Pharmacology. A.R.S. Santos and O. G. Miguel thank Conselho Nacional de Desenvolvimento Científico e Tecnológico for fellowship support.
| |
Footnotes |
|---|
Accepted for publication November 18, 1998.
Received for publication July 16, 1998.
1 This work was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico, Financiadora de Estudos e Projetos, and Programa de Apoio ao Desenvolvimento Científico e Tecnológico (Brazil).
Send reprint requests to: João B. Calixto, Department of Pharmacology, CCB, Universidade Federal ded Santa Catarina, Rua Ferreira Lima, 82, 88015-420, Florianópolis SC, Brazil. E-mail: calixto{at}farmaco.ufsc.br
| |
Abbreviations |
|---|
DPHD, cis-8,10-di-N-propyllobelidiol
hydrochloride dihydrate;
PCPA, DL-p-chlorophenylalanine methyl ester
hydrochloride;
L-ARG, L-arginine;
L-NOARG, NG-nitro-L-arginine;
GABA,
-aminobutyric acid.
| |
References |
|---|
|
|
|---|
2-adrenoceptor, GABAB and
-opioid receptor agonists.
Br J Pharmacol
110:
1049-1054[Medline].
2-mediated supraspinal analgesia in mice.
Life Sci
48:
1721-1727[Medline].
-endorphin-induced antinociception in the mouse.
J Pharmacol Exp Ther
279:
39-46This article has been cited by other articles:
![]() |
G. L. Mendes, A. R. S. Santos, A. Malheiros, V. C. Filho, R. A. Yunes, and J. B. Calixto Assessment of Mechanisms Involved in Antinociception Caused by Sesquiterpene Polygodial J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 164 - 172. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||